{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:52:50Z","timestamp":1788292370192,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,9]],"date-time":"2022-04-09T00:00:00Z","timestamp":1649462400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008363","name":"Danish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.radonc.2022.04.005","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T11:14:56Z","timestamp":1649675696000},"page":"53-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours"],"prefix":"10.1016","volume":"171","author":[{"given":"L.","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.F.","family":"Persson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Nyg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.B.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Borrisova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gaard-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Josipovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Knap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ottosson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Sand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Thing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00f8hl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schytte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2022.04.005_b0005","first-page":"10","article-title":"The HILUS-trial - a prospective Nordic multi-center phase II study of ultra-central lung tumors treated with stereotactic body radiotherapy","volume":"21","author":"Lindberg","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0010","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0015","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0167-8140(19)30481-5","article-title":"OC-0061 EORTC 22113\u20138113 Lungtech trial on SBRT of central lung tumors","volume":"133","author":"Adebahr","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.radonc.2004.07.033","article-title":"Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET\/CT imaging with induction chemotherapy for patients with non-small cell lung cancer","volume":"73","author":"Holloway","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/09553002.2019.1552375","article-title":"Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis","volume":"95","author":"Rim","year":"2019","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.radonc.2022.04.005_b0035","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0040","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.prro.2015.09.012","article-title":"Fatal complications after stereotactic body radiation therapy for central lung tumors abutting the proximal bronchial tree","volume":"6","author":"Haseltine","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.radonc.2018.10.025","article-title":"Radiotherapy quality assurance of SBRT for patients with centrally located lung tumours within the multicentre phase II EORTC Lungtech trial: Benchmark case results","volume":"132","author":"Lambrecht","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0050","doi-asserted-by":"crossref","first-page":"20130653","DOI":"10.1259\/bjr.20130653","article-title":"Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer","volume":"87","author":"Groom","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2022.04.005_b0055","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ejca.2012.02.008","article-title":"Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach","volume":"48","author":"Fairchild","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2022.04.005_b0060","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.ijrobp.2020.11.011","article-title":"Using auto-segmentation to reduce contouring and dose inconsistency in clinical trials: the simulated impact on RTOG 0617","volume":"109","author":"Thor","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.04.005_b0065","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.ijrobp.2009.02.072","article-title":"Lung Adjuvant Radiotherapy Trial Investigators Group. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study","volume":"76","author":"Spoelstra","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.04.005_b0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13014-015-0567-5","article-title":"Lungtech, a phase II EORTC trial of SBRT for centrally located lung tumours - a clinical physics perspective","volume":"11","author":"Lambrecht","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2012.08.008","article-title":"QA makes a clinical trial stronger: evidence-based medicine in radiation therapy","volume":"105","author":"Weber","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0080","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(20)30742-7","article-title":"High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial","volume":"22","author":"Gr\u00f8nberg","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0085","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.tipsro.2019.05.001","article-title":"Assessment of contour variability in target volumes and organs at risk in lung cancer radiotherapy","volume":"10","author":"Tsang","year":"2019","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0090","doi-asserted-by":"crossref","unstructured":"Petkar I, McQuaid D, Dunlop A, Tyler J, Hall E, Nutting C. Inter-observer variation in delineating the pharyngeal constrictor muscle as organ at risk in radiotherapy for head and neck cancer. Front Oncol 20219;11:644767.","DOI":"10.3389\/fonc.2021.644767"},{"key":"10.1016\/j.radonc.2022.04.005_b0095","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clon.2019.05.009","article-title":"Radiotherapy quality assurance for the CHHiP trial: conventional versus hypofractionated high-dose intensity-modulated radiotherapy in prostate cancer","volume":"31","author":"Naismith","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2022.04.005_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2008.12.016","article-title":"Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus","volume":"66","author":"Song","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2022.04.005_b0105","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ijrobp.2010.04.056","article-title":"Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial","volume":"80","author":"Bral","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.04.005_b0110","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.radonc.2019.11.001","article-title":"Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91","volume":"142","author":"de Jong","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.radonc.2020.11.032","article-title":"Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer","volume":"156","author":"Thomas","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0120","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/0284186X.2017.1279750","article-title":"Interobserver delineation uncertainty in involved-node radiation therapy (INRT) for early-stage Hodgkin lymphoma: on behalf of the Radiotherapy Committee of the EORTC lymphoma group","volume":"56","author":"Aznar","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2019.04.012","article-title":"Impact of deviations in target volume delineation \u2013 Time for a new RTQA approach?","volume":"137","author":"Cox","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.radonc.2017.06.022","article-title":"Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): design and early dosimetric results of a randomized, multi-centre phase-III study","volume":"124","author":"M\u00f8ller","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.radonc.2020.06.015","article-title":"Delineation of whole heart and substructures in thoracic radiation therapy: National guidelines and contouring atlas by the Danish Multidisciplinary Cancer Groups","volume":"150","author":"Milo","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.04.005_b0145","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ijrobp.2010.07.1977","article-title":"Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus","volume":"81","author":"Kong","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2022.04.005_b0150","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2020.05.038","article-title":"Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines","volume":"150","author":"Mir","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2016.08.019","article-title":"Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose","volume":"121","author":"M\u00f8ller","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0160","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmp.2017.04.010","article-title":"Organs at risk in lung SBRT","volume":"44","author":"De Rose","year":"2017","journal-title":"Phys Med"},{"key":"10.1016\/j.radonc.2022.04.005_b0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.semradonc.2015.11.001","article-title":"Validity of current stereotactic body radiation therapy dose constraints for aorta and major vessels","volume":"26","author":"Xue","year":"2016","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0170","first-page":"1","article-title":"Local control after stereotactic body radiotherapy of centrally located lung tumours","volume":"14","author":"Khalil","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0175","doi-asserted-by":"crossref","unstructured":"Hanna GG, McDonald F, Murray L et al. UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy: Reply to Ghafoor et al. Clin Oncol (R Coll Radiol) 2018;30:456.","DOI":"10.1016\/j.clon.2018.03.012"},{"key":"10.1016\/j.radonc.2022.04.005_b0180","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2307\/1932409","article-title":"Measures of the amount of ecologic association between species","volume":"26","author":"Dice","year":"1945","journal-title":"Ecology"},{"key":"10.1016\/j.radonc.2022.04.005_b0185","doi-asserted-by":"crossref","unstructured":"Ruckligde W. Efficient visual recognition using the Hausdorff distance. Lect. Notes Comput. Sci., Springer 1996; pp. 27-42.","DOI":"10.1007\/BFb0015093"},{"key":"10.1016\/j.radonc.2022.04.005_b0190","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/JTO.0b013e318279155f","article-title":"Patterns-of-care for thoracic stereotactic body radiotherapy among practicing radiation oncologists in the United States","volume":"8","author":"Daly","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0195","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/JTO.0b013e318293dc45","article-title":"Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis","volume":"8","author":"Guckenberger","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0200","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/COC.0000000000000162","article-title":"Stage I lung SBRT clinical practice patterns","volume":"40","author":"Corso","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0205","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jtho.2019.04.018","article-title":"Safety and effectiveness of stereotactic ablative radiotherapy for ultra-central lung lesions: a systematic review","volume":"14","author":"Chen","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.radonc.2016.08.019","article-title":"Adaptive radiotherapy for advanced lung cancer ensures target coverage and decreases lung dose","volume":"121","author":"M\u00f8ller","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0215","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1080\/02841860802282786","article-title":"The role of image guidance in respiratory gated radiotherapy","volume":"47","author":"Korreman","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0220","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3109\/0284186X.2010.500303","article-title":"Evaluation of setup accuracy for NSCLC patients; studying the impact of different types of conebeam CT matches based on whole thorax, columna vertebralis, and GTV","volume":"49","author":"Ottosson","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2022.04.005_b0225","doi-asserted-by":"crossref","DOI":"10.1002\/mp.13053","article-title":"Validation of the Acuros XB dose calculation algorithm versus Monte Carlo for clinical treatment plans","author":"Hoffmann","year":"2018","journal-title":"Med Phys"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402200175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402200175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:20:51Z","timestamp":1759123251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402200175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":45,"alternative-id":["S016781402200175X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2022.04.005","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thorough design and pre-trial quality assurance (QA) decrease dosimetric impact of delineation and dose planning variability in the STRICTLUNG and STARLUNG trials for stereotactic body radiotherapy (SBRT) of central and ultra-central lung tumours","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2022.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}